Life Medical Sciences
This article was originally published in The Gray Sheet
Executive Summary
Files registration statement with the Securities and Exchange Commission for a proposed secondary offering of up to 500,000 units at $16.78 each. The units consist of two shares of common stock and one Class A warrant. Each Class A warrant, with an exercise price of $9, entitles the holder to one share of common stock and one Class B warrant (with an exercise price of $13.50 for one share). Proceeds would be used for "expenditures relating to the commercialization" of the development stage firm's Skin- Stretching device for wound closure, for which a 510(k) was filed in Dec. 1992; R&D; clinical trials of wound dressing gel technology; "working capital"; and debt repayment. The units will be offered through broker-dealers. The Princeton, New Jersey firm netted $5.4 mil. from an initial public offering completed in October 1992....
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.